NKG2D, a lectin like immunoreceptor expressed by NK cells and cytotoxic T cells, triggers cytotoxicity and cytokine production by NK cells and enhances T cell responses. Ligands for NKG2D are class I MHC-like molecules including the Rae1/Mult1/ULPB family in humans and mice, and the MICA/MICB ligands in humans. The ligands are poorly expressed by normal cells and induced in stressed cells, cancer cells and pathogen- infected cells. Ligand induction is related to disease-associated signals. In addition to the DNA damage response, which induces ligand expression in transformed cells, we have recently uncovered two additional mechanisms of ligand regulation, which we propose to investigate in this proposal. Two of the aims are directed at developing a deeper molecular understanding of pathways that regulate NKG2D ligands.
Aim 1 is to identify the regulatory proteins and E3 ligases that mediate a novel mode of NKG2D ligand regulation, whereby the protein is rapidly degraded in normal cells, but stabilized in stressed cells exposed to heat shock or UV light, or in cancer cells.
Aim 2 is to probe a newly discovered mechanism that links cellular proliferation to transcription of the Rae1e NKG2D ligand, and entails identification of the responsible transcription factors and probing instances where NKG2D ligands are repressed in advanced cancer cells.
The third aim grew from the discovery that cellular proliferation is apparently a sufficient signal to induce Rae1 expression, along with preliminary data that suggest that such expression is not always sufficient to render cells sensitive to NK elimination in vivo. These findings led to the hypothesis that multiple disease associated signals must converge to render cells sensitive, and as such represent a "cancer- associated pattern". Whereas proliferation may induce NKG2D ligands, other signals associated with tumor suppressor activation may be necessary for actual elimination of nascent tumor cells.
The third aim proposes a suite of experiments to test this hypothesis in the context of a liver tumor system in which tumor suppressor function can be switched on and off with doxycycline. The proposed experiments will lead to a deeper understanding of how disease-associated signals are integrated to regulate the sensitivity of cells to immune surveillance. The molecular studies should identify new targets for therapeutic augmentation of the immune response in the context of cancer or infections, or for dampening NKG2D-dependent responses in the context of chronic inflammatory diseases.
This research addresses the regulation of molecules that are displayed only on cancer cells and infected cells, and which stimulate killer cells of the immune system to attack and eliminate cells expressing the ligands. These molecules are part of a system that provides a first line defense against cancer and many infections, but that can also cause autoimmunity when things go wrong. We propose to identify the molecular pathways that "turn-on" these molecules in diseased cells, to uncover mechanisms responsible for immune control of rapidly dividing and stressed cancer cells. Our studies will provide new approaches for enhancing the immune response against cancer and infection, and inhibiting its role in autoimmunity.
|Ardolino, Michele; Raulet, David H (2016) Cytokine therapy restores antitumor responses of NK cells rendered anergic in MHC I-deficient tumors. Oncoimmunology 5:e1002725|
|Tovbis Shifrin, Nataliya; Kissiov, Djem U; Ardolino, Michele et al. (2016) Differential Role of Hematopoietic and Nonhematopoietic Cell Types in the Regulation of NK Cell Tolerance and Responsiveness. J Immunol 197:4127-4136|
|Clark, Sarah E; Filak, Holly C; Guthrie, Brandon S et al. (2016) Bacterial Manipulation of NK Cell Regulatory Activity Increases Susceptibility to Listeria monocytogenes Infection. PLoS Pathog 12:e1005708|
|Raulet, David H (2015) Bone Marrow Cell Rejection, MHC, NK Cells, and Missing Self Recognition: Ain't That Peculiar (with Apologies to Marvin Gaye). J Immunol 195:2923-5|
|Ardolino, Michele; Hsu, Joy; Raulet, David H (2015) Cytokine treatment in cancer immunotherapy. Oncotarget 6:19346-7|
|Gowen, Benjamin G; Chim, Bryan; Marceau, Caleb D et al. (2015) A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells. Elife 4:|
|Iannello, Alexandre; Raulet, David H (2014) Immunosurveillance of senescent cancer cells by natural killer cells. Oncoimmunology 3:e27616|
|Lam, Adeline R; Le Bert, Nina; Ho, Samantha S W et al. (2014) RAE1 ligands for the NKG2D receptor are regulated by STING-dependent DNA sensor pathways in lymphoma. Cancer Res 74:2193-203|
|Marcus, Assaf; Gowen, Benjamin G; Thompson, Thornton W et al. (2014) Recognition of tumors by the innate immune system and natural killer cells. Adv Immunol 122:91-128|
|Ardolino, Michele; Azimi, Camillia S; Iannello, Alexandre et al. (2014) Cytokine therapy reverses NK cell anergy in MHC-deficient tumors. J Clin Invest 124:4781-94|
Showing the most recent 10 out of 41 publications